Levofloxacino Serraclinics (Levofloxacin)

Levofloxacin is a broad‑spectrum fluoroquinolone used to treat bacterial infections in several organ systems.

• Community‑acquired pneumonia: eradicates the typical bacterial pathogens responsible for acute lung infection.
• Hospital‑acquired pneumonia: provides coverage against resistant Gram‑negative and Gram‑positive organisms.
• Complicated urinary tract infections: eliminates causative bacteria in upper and lower urinary tracts.
• Complicated intra‑abdominal infections: targets mixed aerobic and anaerobic flora.
• Skin and soft tissue infections: treats serious bacterial cellulitis and wound infections.
• Bacterial prostatitis: penetrates prostatic tissue to clear infection.

• Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme‑DNA complex, it prevents the resealing of DNA strands, leading to bacterial cell death. This bactericidal action is effective against a wide range of Gram‑negative and Gram‑positive organisms.

Levofloxacin may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: often self‑limiting but may be watery.
• Headache: transient and usually resolves without intervention.
• Dizziness: occasional sensation of light‑headedness.
• Rash: non‑specific skin eruption.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, often linked to sudden activity.
• QT interval prolongation: may precipitate cardiac arrhythmias.
• Clostridioides difficile infection: severe colitis following gut flora disruption.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Peripheral neuropathy: numbness or tingling in extremities.

Levofloxacin requires careful assessment of patient‑specific factors before use.

• Renal impairment: dose adjustment may be needed based on creatinine clearance.
• Hepatic impairment: monitor liver function tests during therapy.
• QT prolongation risk: avoid in patients with known cardiac conduction disorders.
• Tendon injury risk: advise patients to refrain from excessive physical activity during treatment.
• Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
• Antacid co‑administration: separate dosing by at least 2 hours to prevent absorption reduction.
• Store below 25°C: keep in original container, protect from moisture and light.

Levofloxacin can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: markedly reduce levofloxacin absorption.
• Other fluoroquinolones: additive toxicity, especially tendon and CNS effects.
• QT‑prolonging agents (e.g., macrolides, antiarrhythmics): increase risk of cardiac arrhythmias.
• Warfarin: may potentiate anticoagulant effect, raising INR.
• NSAIDs: heightened seizure risk in susceptible individuals.

Moderate Interactions (Monitor Closely)

• Corticosteroids: combined use raises tendon rupture probability.
• Theophylline: levofloxacin can increase serum theophylline levels.
• Cyclosporine: may elevate cyclosporine concentrations.
• Digoxin: monitor for possible increased serum digoxin.
• Diabetic agents (e.g., insulin, sulfonylureas): risk of hypoglycemia may be enhanced.